General
Preferred name
DY 268
Synonyms
DY-268 ()
DY268 ()
P&D ID
PD069418
CAS
1609564-75-1
Tags
available
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION DY268 is a farnesoid X receptor (FXR) antagonist (IC50=7.5 nM). It inhibits FXR transactivation in a cell-based assay with an IC50 value of 468 nM. DY268 can be used in the study of drug-induced liver injury (DILI)[1][2].
PRICE 138
DESCRIPTION DY-268, a pyrazol carboamide derivative, has been found to be a FXR antagonist that could be significant in studies of the biological activities of FXR. IC50: 7.5 nM. (BOC Sciences Bioactive Compounds)
DESCRIPTION DY268 is a compound based on trisubstituted pyrazolamide without any FXR agonist activity and cytotoxicity and can be used as an effective FXR antagonist (IC50 = 7.5 nM). (TargetMol Bioactive Compound Library)
DESCRIPTION Potent and selective PPARdelta agonist (Tocris Bioactive Compound Library)
Compound Sets
10
Axon Medchem Screening Library
BOC Sciences Bioactive Compounds
Cayman Chemical Bioactives
EUbOPEN Chemogenomics Library
Guide to Pharmacology
Mcule NIBR MoA Box Subset
MedChem Express Bioactive Compound Library
Novartis Chemogenetic Library (NIBR MoA Box)
TargetMol Bioactive Compound Library
Tocris Bioactive Compound Library
External IDs
10
Properties
(calculated by RDKit )
Molecular Weight
560.21
Hydrogen Bond Acceptors
7
Hydrogen Bond Donors
1
Rotatable Bonds
8
Ring Count
5
Aromatic Ring Count
4
cLogP
4.5
TPSA
102.76
Fraction CSP3
0.27
Chiral centers
0.0
Largest ring
6.0
QED
0.34
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Target
FXR
FXR antagonist
Primary Target
LXR-like Receptors
MOA
Antagonist
NR1H4 gene inhibitor
Member status
member
Pathway
Metabolic Enzyme/Protease
Metabolism
Solubility
DMSO: 100 mM
Recommended Cell Concentration
1 uM
Source data